Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that patients with androgenetic alopecia had a higher prevalence of metabolic syndrome compared to healthy controls.

This article provides an endocrine perspective on evaluating and managing hirsutism but reports no new research findings.

In this randomized controlled trial, researchers found that a 2.5 mg daily dose of oral minoxidil was more effective than a 1 mg dose in improving hair growth parameters in patients with androgenetic alopecia over three months, with both doses being well tolerated.

In this correspondence, researchers reported that very-low-dose oral minoxidil (0.25 mg/d) showed some effectiveness in stabilizing trichoscopic parameters in male androgenetic alopecia. However, their analysis suggests that higher doses (2.5–5 mg/d) may lead to better clinical responses with similar rates of adverse events.

This review evaluates six primary studies on androgenetic alopecia treatments and suggests topical minoxidil or finasteride as first-line options, recommending further research into treatments and practice guidelines.

This study reports that comorbidities and anti-androgen therapy were associated with lower SARS-CoV-2 vaccination rates among patients with androgenetic alopecia, emphasizing the need to promote vaccination within this group.

This review discusses alternative androgen pathways, including the "backdoor" pathway and pathways to 11-oxygenated steroids, and reports no new clinical results; the authors aim to clarify these concepts for better patient treatment.

In this study, QR678® and QR678 Neo® injections significantly improved hair density and thickness in women with PCOS-related alopecia over eight sessions, with effects lasting over a year.

This article reviews the mechanism, use, and alternatives for finasteride in dermatology and provides no new clinical results.

In this study, men with AGA who took finasteride 5 mg daily for 24 months showed a significant increase in hair counts compared to those who received a placebo.